Individual experiences vary considerably, and not everyone will notice changes in libido or sexual function
What the Dose-Response Data Actually Shows GLP-1 receptor agonist efficacy is dose-dependent
Journal of Women's Health (2002), 19 (11), 19551962
Supplementary search techniques (e.g., Google Scholar, citation searching, etc.) were employed to ensure no publication was overlooked during the literature search process
In response, the medical community and compounding space shifted toward alternatives with a perceived improved safety profile: Ipamorelin a more selective growth hormone secretagogue CJC-1295 a growth hormone-releasing hormone (GHRH) analog These compounds were seen as a next generation option, offering many of the same benefits with potentially fewer side effects
Thirdly, implantable devices could be an option to replace injections